Aurinia Pharmaceuticals Inc.（AUPH）股票分析AUPHAurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. It sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the European and Japanese market. The Company sells encapsulated voclosporin to its collaboration partner, Otsuka, which Otsuka then sells to customers in its territories. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Aurinia Pharmaceuticals Inc is a good buy right now due to its current price of $16.86, a strong gross margin of 92.12%, and a forward P/E ratio of 11.83, suggesting solid valuation. The recent acquisition of shares by the CEO for $12.5 million indicates confidence in the company's future. However, the main risk is the potential volatility indicated by an implied volatility of 54.66%.

5 analysts cover AUPH: 5 rate it Buy, 0 Hold and 0 Sell. The average price target is 16.50.